Ocugen

United States
Beechwood Trails, Ohio, United States

Company profile

Ocugen company profile

Ocugen is a clinical-stage biopharmaceutical company focused on discoverinOcugen Inc is a clinical-stage biopharmaceutical business focused on discovering, developing, and commercializing gene treatments to cure blinding illnesses, as well as developing a COVID-19 vaccine to save lives. The biologic product candidate aims to provide better therapy to patients with underserved diseases such as wet age-related macular degeneration, diabetic macular edema, and diabetic retinopathy using the breakthrough modifier gene therapy platform.

Business identity

Phone number
(720)859-3549
Operating status
Active
Company type
For Profit
Employee range
51-100 employees
Revenue range
$0-$1M
Founded
2013-01-01, Year

Headquarters

Country code
US
Continent
North America

Capital profile

Funding and company signals

Funding stage
IPO
Funding rounds
10
Total equity funding
$284M
Last funding
Post IPO Equity / $22.5M / 2026-01-21
Last equity funding
Post IPO Equity / $22.5M
Investors
11
Lead investors
5
Founders
2
Articles
325
Exited on
2019-04-08

Founders and investors

Founders

Shankar MusunuriUday B. Kompella

Lead investors

Abdi Ibrahim PharmaceuticalsAvenue Capital GroupJanus Henderson InvestorsLancaster GroupRTW Investments

Investors

Abdi Ibrahim PharmaceuticalsAvenue Capital GroupJanus Henderson InvestorsROTH Capital PartnersRTW Investments